MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment of MSA-P Phase 1 randomized, controlled trial to ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - MELBOURNE, Australia and SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH ...

VALBY, Denmark, Oct. 2, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that pipeline developments regarding amlenetug, a novel investigational molecule for the potential treatment of ...

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...